linvoseltamab

{
  "id": "MLC-T-ONC-014795",
  "term": "linvoseltamab",
  "field": "Oncology and biomedicine",
  "definition": "A human, immunoglobulin G4 (IgG4) bispecific antibody directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, linvoseltamab targets and binds to both CD3 on cytotoxic T lymphocytes (CTLs) and BCMA on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, leading to CTL-mediated killing of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.",
  "synonyms": [
    "BCMA x CD3 bispecific antibody REGN5458",
    "anti-BCMA/CD3 bispecific antibody REGN5458",
    "anti-BCMA x anti-CD3 bispecific antibody REGN5458"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/linvoseltamab/"
}